OXFORD BIOMEDICA SEEKS TO RAISE UP TO 30 MLN STG

A A

Britain's Oxford Biomedica (OXB.L: Quote, Profile, Research) said on Wednesday it planned to raise up to 30 million pounds ($53 million)in a placing and open offer of its shares to fund final stage clinical trials of its key drug, TroVax for cancer. The company said it planned to start a final Phase III clinical trial in 2006 and that it was in talks with potential commercial partners for the experimental medicine.

Reuters (http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh69346_2005-11-02_14-35-40_wla3419_newsml)